Moleculin Biotech Secures $6 Million Through Warrant Agreement

Moleculin Biotech ( (MBRX) ) has shared an update.

On August 27, 2025, Moleculin Biotech entered into an agreement with certain warrant holders for the immediate exercise of existing warrants to purchase up to 16,216,216 shares of common stock, generating approximately $6.0 million in gross proceeds. In exchange, Moleculin will issue new warrants for up to 64,864,864 shares, exercisable at $0.55 per share upon shareholder approval. This strategic move is expected to provide the company with additional working capital and support its ongoing clinical developments.

The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases, while other programs target brain tumors, pancreatic cancer, and pathogenic viruses.

Average Trading Volume: 6,279,836

Technical Sentiment Signal: Sell

Current Market Cap: $11.91M

Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.